Best practices as recommended by WHO and United States Pharmacopoeia are being implemented for performing tests on therapeutic goods.
Recent Updates
- Recall Alert: RECALL OF XARELTO 15MG TABLET, BATCH NO. BXK4E11, DUE TO A LABELING ERROR ON SECONDARY PACKAGING May 23, 2025
- Rapid Alert: CRACKDOWN AGAINST FALSIFIED/SPURIOUS DRUGS May 22, 2025
- Stakeholders are invited to comment on Draft Guidelines on Emergency Use Authorization by 06th June, 2025 May 22, 2025
- Drugs Research Rules 1978 (Amended) May 22, 2025
- Training Session on MDMC Licensing and Product Registration Portal on: https://www.facebook.com/OfficialDRAP/ May 21, 2025
- Comments are invited on revision of Guidelines on Inspection of Good Clinical Practices for Clinical Trials May 21, 2025
- Stakeholders Comments are invited on revision of Guidelines for Conduct of Clinical Research in Pakistan May 21, 2025
- Minutes of the 346th Meeting of the Registration Board Held on 22nd April, 2025 May 21, 2025
- Rapid Alert: CRACKDOWN AGAINST FALSIFIED/SPURIOUS DRUGS May 19, 2025
- Training of online CPI module for submission of applications(Wednesday May 21, 10:30 AM) May 19, 2025
Chief Executive Officer
- Dr. Obaidullah

Guidelines
Regulatory compliance is essential and indispensable in order to assure the safety, quality and efficacy of therapeutic goods. Guidance documents published by the Authority are meant to explain the current interpretation or policy for better understanding of the industry and

Quality Control Labs
For ensuring quality therapeutic goods, a network of quality control laboratories has been established. DRAP approved products and suspect therapeutic goods are tested for their quality in accordance with best international practices. To keep the citizens safe from substandard and

Therapeutic Products Recalls
The Recalled Product Index provides access to consumers, healthcare professionals, industry, hospitals and sale outlets related to the information of recalled action taken for defective therapeutic goods. The following section provides an index of recalled actions in which a public

Health Professional Alerts
DRAP’s issues safety updates and alerts related to the therapeutic goods in order to ensure that healthcare professionals and other stakeholders have timely access to the relevant information on safety, quality and efficacy issues or benefit/risk evaluations of the drugs,

Medicine Availability
The Drug Regulatory Authority of Pakistan (DRAP) is committed to safeguard public health by ensuring the consistent availability of safe, efficacious, and quality medicines nationwide. Recognizing the critical impact of drug shortages, particularly of essential and lifesaving medicines, on patient
eApp and centralized Case Management System
We are delighted to announce that DRAP has enabled eApp for Drug Licensing & Registration application submissions. Moreover, we have introduced centralized Case Management System in the same portal for enhanced efficiency and transparency.
Do you know?
DRAP ensures that every drug, medical device or cosmetic, alternative medicine and health product must have a certain standard of quality and is safe and effective for your use. See in links below how it is done and what to do in case you find a suspect therapeutic good.